HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL.

AbstractBACKGROUND:
We prospectively evaluated the immunological status, immune recovery and risk of infection in pediatric ALL patients treated on the BFM 95 protocol.
PROCEDURE:
Humoral and cellular immunity were evaluated in 72 children with ALL at the end of intensive therapy and values were compared to those at the completion of therapy and 6-monthly. Parameters investigated included lymphocyte subpopulation by flow cytometry, immunoglobulin levels by nephelometry, antibody titers to previous immunizations and delayed hypersensitivity with skin testing. Immune responses were correlated to duration of therapy, CNS radiotherapy, age and sex.
RESULTS:
Humoral immunity was severely depressed by the end of intensive therapy with low immunoglobulin levels and CD19, improved after therapy cessation. Cellular immune responses were normal at the end of intensive treatment but declined significantly by the end of therapy and both CD4 and CD8 remained low at later evaluation points whereas CD4/CD8 ratio was increasing. Duration of therapy and CNS radiotherapy did not affect the rate of immune recovery whereas female had higher CD19, CD45RO, and IgM and children >7 years had higher CD19 and lower CD16 and CD3DR. Among immunized children, 86.7% maintained protective antibodies to MMR and 63% to polio. Despite impairment of immunity, infections outside the neutropenic periods were common viral illnesses.
CONCLUSION:
Humoral immunity was depressed in children with ALL at the end of intensive therapy but began to recover after cessation of therapy. In contrast, cellular immunity declined significantly by the end of therapy and remained abnormal for at least 1 year post-therapy.
AuthorsSofia Kosmidis, Margarita Baka, Despina Bouhoutsou, Dimitrios Doganis, Constantina Kallergi, Nikolaos Douladiris, Apostolos Pourtsidis, Maria Varvoutsi, Fotini Saxoni-Papageorgiou, Helen Vasilatou-Kosmidis
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 50 Issue 3 Pg. 528-32 (Mar 2008) ISSN: 1545-5017 [Electronic] United States
PMID17853465 (Publication Type: Journal Article)
Copyright(c) 2007 Wiley-Liss, Inc.
Chemical References
  • Antibodies, Viral
  • Antigens, CD
Topics
  • Adolescent
  • Agammaglobulinemia (chemically induced)
  • Antibodies, Viral (blood)
  • Antibody Formation (drug effects)
  • Antigens, CD (analysis)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cranial Irradiation (adverse effects)
  • Disease Susceptibility
  • Female
  • Humans
  • Immunity, Cellular (drug effects)
  • Immunocompromised Host
  • Infant
  • Infections (epidemiology)
  • Leukemia-Lymphoma, Adult T-Cell (drug therapy, immunology, radiotherapy)
  • Male
  • Neutropenia (chemically induced)
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, immunology, radiotherapy)
  • Prospective Studies
  • Skin Tests
  • T-Lymphocyte Subsets (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: